Langerhans cell histiocytosis (LCH)
Langerhans cell histiocytosis is a disorder in which a small group of immune cells with a faulty growth signal (most often a BRAF mutation) pile up in bone, skin, pituitary or organs. It ranges from a single bone lesion that heals after biopsy to a life-threatening disease of infants. A year of gentle chemotherapy cures most children, and BRAF or MEK inhibitors rescue those with resistant disease.
Overview
LCH is now understood as an inflammatory myeloid neoplasm: clonal cells of the mononuclear phagocyte lineage carry activating MAPK-pathway mutations, most often BRAF V600E (about half of cases) and MAP2K1, with the remainder having other RAS-MAPK lesions. The cell of origin, a bone-marrow or blood myeloid precursor versus a tissue dendritic cell, determines extent: mutations arising early give multisystem disease with risk-organ involvement (liver, spleen, marrow), while later lesions give single bone or skin disease. Pituitary involvement causes diabetes insipidus, and a minority of children develop a late neurodegenerative syndrome from mutated cells in the brain.
Treatment is stratified. Single-system bone or skin disease often needs only biopsy or curettage, observation or local therapy. Multisystem disease is treated with vinblastine and prednisone: the Histiocyte Society trials LCH-I to LCH-III showed that early response predicts survival and that prolonging therapy to 12 months reduces reactivation (LCH-III, Blood 2013); LCH-IV is refining duration and testing intensification for non-responders. Children with risk-organ involvement who do not respond quickly move to salvage (cladribine and cytarabine, or clofarabine). For refractory BRAF V600E disease, vemurafenib produces rapid responses in almost all children (Donadieu, JCO 2019), and dabrafenib with or without trametinib is used; MEK inhibitors cover MAP2K1 and other mutations. Responses to targeted therapy are near universal but reactivation on stopping is common, so the durability and safety of long-term inhibitors in young children is the central question.
Adult LCH, including smoking-related pulmonary LCH, is managed with cladribine or cytarabine and MAPK inhibitors, and is now covered by the same Histiocyte Society and NCCN guidance. Neurodegenerative LCH, once untreatable, responds partially to MAPK inhibition, giving a reason to detect it early with MRI.
State of the art today
- LCH is a MAPK-driven myeloid neoplasm; BRAF V600E in tissue and blood is a diagnostic, prognostic and monitoring marker.
- Twelve months of vinblastine-prednisone cures most children with multisystem disease and early response is the key prognostic signal (LCH-III).
- BRAF and MEK inhibitors rescue nearly every child with refractory BRAF-mutant disease, but reactivation after stopping means duration is unresolved.
- Neurodegenerative LCH, the most feared late complication, is partially reversible with MAPK inhibition if caught early.
Where it starts and where it drains
Leukaemias, myeloma and MDS live in the marrow and blood; lymphomas grow in lymph nodes and spleen. The node stations are the disease map, not a route of spread, and staging counts them.
- Bone marrow (leukaemia, MDS, MPN, myeloma)Single-system LCH (bone, skin, lymph node) · Multisystem LCH without risk-organ involvement · Multisystem LCH with risk-organ involvement (liver, spleen, haematopoietic) · CNS-risk lesions and pituitary LCH (diabetes insipidus) · Neurodegenerative LCH · Pulmonary LCH (adults, smoking-related) · Mixed LCH / Erdheim-Chester disease (adults)
- Lymph node germinal centre (lymphomas)
- Spleen
- Blood (leukaemic phase)
- Lytic bone lesions (myeloma)
- Skin and extranodal sitesSingle-system LCH (bone, skin, lymph node) · CNS-risk lesions and pituitary LCH (diabetes insipidus)
- cervical
- axillary
- mediastinal
- para-aortic and mesenteric
- inguinal
In lymphoma the node stations are the disease itself; staging (Ann Arbor / Lugano) counts how many regions and sides of the diaphragm are involved.
Same organ: Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia, Chronic myeloid leukaemia (CML), Diffuse large B-cell lymphoma, Follicular lymphoma, Hodgkin lymphoma, Mantle cell lymphoma, Multiple myeloma, Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Waldenström macroglobulinaemia, Hairy cell leukaemia, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Blastic plasmacytoid dendritic cell neoplasm (BPDCN), Burkitt lymphoma, HIV-associated (AIDS-related) lymphomas, Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Systemic mastocytosis, Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms, Post-transplant lymphoproliferative disorder (PTLD)
Roughly 5 cases per million children per year, most under ten; also occurs in adults, often in the lung of smokers (NCI PDQ).
- Liquid biopsy (ctDNA)Standard of care
- AI in radiologyEstablished
- cfDNA fragmentomicsEstablished
- Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood)Standard of care
- DNA methylation profilingEstablished
- HCC surveillance in cirrhosis (ultrasound + AFP)Standard of care
- A 28-day national pathway for people with a positive multi-cancer blood test
- A breath test to rule out cancer in people with vague symptoms
- A cancer blood test for older people arriving at A&E with unexplained symptoms
- A legislated, publicly reported 28-day standard from urgent referral to diagnosis
- A live national dashboard of stage at diagnosis as the scorecard for early detection
- A single 'cancer check at 60' appointment bundling all screening tests
Background: Alpha-fetoprotein (AFP), Barrett's oesophagus, CA 19-9, Early detection, Faecal immunochemical test (FIT). Also on OnCo: Symptoms and red flags · Early detection roadmap.
Where the cases are
No country-level case numbers. This cancer is not mapped to a GLOBOCAN site.
Biopsy or curettage with observation; intralesional steroid, topical therapy or indomethacin for symptomatic lesions; systemic therapy for multifocal bone or CNS-risk lesions.
Vinblastine and prednisone for 12 months (LCH-III), with response assessment at 6 weeks; LCH-IV tests further tailoring of duration and intensity.
Cladribine plus cytarabine or clofarabine salvage; BRAF inhibitor (vemurafenib or dabrafenib, with trametinib) for BRAF V600E, MEK inhibitor for MAP2K1-mutant disease.
MAPK-pathway inhibition (BRAF or MEK inhibitor) with neurological monitoring; early MRI detection in children with pituitary or craniofacial disease.
Subtypes & biomarkers
top- Single-system LCH (bone, skin, lymph node)
- Multisystem LCH without risk-organ involvement
- Multisystem LCH with risk-organ involvement (liver, spleen, haematopoietic)
- CNS-risk lesions and pituitary LCH (diabetes insipidus)
- Neurodegenerative LCH
- Pulmonary LCH (adults, smoking-related)
- Mixed LCH / Erdheim-Chester disease (adults)
- BRAF V600E in lesion tissue and cell-free DNA (disease burden and monitoring)
- MAP2K1 and other MAPK alterations
- Risk-organ involvement at diagnosis
- Response at week 6 (predicts outcome in LCH-III)
- Pituitary MRI and posterior pituitary function
- Brain MRI for neurodegenerative change
Target prevalence in this cancer
- 1953Lichtenstein unifies eosinophilic granuloma, Hand-Schuller-Christian and Letterer-Siwe disease as histiocytosis X
- 1973Langerhans cell identified as the lesional cell
Nezelof finds Birbeck granules in the lesions.
- 1991Histiocyte Society launches LCH-I
First international randomised trial in LCH.
- 2010BRAF V600E discovered in LCH
Badalian-Very and colleagues (Blood) show LCH is a clonal MAPK-driven neoplasm.
- 2013LCH-III: 12 months of therapy reduces reactivation
Gadner and colleagues (Blood 2013).
- 2014Cell of origin explains extent
Berres and colleagues (JEM) show BRAF V600E in myeloid precursors in high-risk disease.
- 2019Vemurafenib in refractory childhood LCH
Donadieu and colleagues (JCO) report responses in nearly all BRAF V600E children, with reactivation after stopping.
Open problems, and what is being done about each
How long to give BRAF or MEK inhibitors and how to stop them without reactivation; combination with chemotherapy to allow cessation is being tested in the Histiocyte Society and NACHO networks.
Preventing and treating neurodegenerative LCH; MRI surveillance and early MAPK inhibition are the current approach.
Permanent sequelae (diabetes insipidus, growth failure, hearing loss, sclerosing cholangitis) in survivors of risk-organ disease.
and how the field plans to fix it →What is being done about thisSide effects and quality of lifeAvailable now- Survivorship care and late-effects surveillanceEstablished
- Cardio-oncologyEstablished
- Exercise & lifestyle oncologyEstablished
- Geriatric assessmentEstablished
- IMRT / IGRT (modern external beam)Standard of care
- Oncology nutrition assessment and medical nutrition therapyEstablished
In trialsIdeas and roadmaps- A cheap old tablet to restore appetite
- A coordinated FLASH radiotherapy evidence programme with shared dose-rate standards
- A dedicated programme for cachexia and treatment toxicity research
- A dietitian in every gastrointestinal and head and neck tumour board
- A funded programme of organ-preservation trials to avoid radical surgery
- A lifelong late-effects registry linked to every treatment for adult survivors
Background: CTCAE toxicity grading (grade 3-4 adverse events), De-escalation, escalation and response-adapted therapy, Immune-related adverse events (irAEs), Quality of life, Toxicity grade. Also on OnCo: Side effects, symptom first · Immune-related side effects · Toxicity compare · Survivorship planner.
Adult LCH is under-recognised and under-studied; shared paediatric-adult guidelines are a first step.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Expert centres
topCentres linked to this cancer in OnCo
- Histiocyte SocietyPitman, USvia this cancer, LCH-III, Vinblastine
- Children's Oncology Group (COG)Monrovia, CA, USvia this cancer
- via this cancer
- Wellcome Sanger InstituteHinxton, GBvia BRAF
Questions to ask
topQuestions to ask your oncologist about Langerhans cell histiocytosis
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Why: Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example BRAF V600E in lesion tissue and cell-free DNA, MAP2K1 and other MAPK alterations, Risk-organ involvement at diagnosis, Response at week 6, Pituitary MRI and posterior pituitary function), and what were the results?Why: These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Why: Recognised subtypes for this cancer include Single-system LCH, Multisystem LCH without risk-organ involvement, Multisystem LCH with risk-organ involvement.
- Is germline (inherited) genetic testing recommended for me or my family?Why: Inherited variants can change treatment and matter for relatives.
Single-system bone or skin
- For my situation (single-system bone or skin), which of the standard options do you recommend and why?Why: Guideline options include: Biopsy or curettage with observation; intralesional steroid, topical therapy or indomethacin for symptomatic lesions; systemic therapy for multifocal bone or CNS-risk lesions.
- Am I a candidate for Vinblastine, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Multisystem LCH (first line)
- For my situation (multisystem lch (first line)), which of the standard options do you recommend and why?Why: Guideline options include: Vinblastine and prednisone for 12 months (LCH-III), with response assessment at 6 weeks; LCH-IV tests further tailoring of duration and intensity.
- Am I a candidate for Vinblastine, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of LCH-III apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Refractory risk-organ disease or reactivation
- For my situation (refractory risk-organ disease or reactivation), which of the standard options do you recommend and why?Why: Guideline options include: Cladribine plus cytarabine or clofarabine salvage; BRAF inhibitor (vemurafenib or dabrafenib, with trametinib) for BRAF V600E, MEK inhibitor for MAP2K1-mutant disease.
- Am I a candidate for Cladribine, Vemurafenib, Dabrafenib + trametinib, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Neurodegenerative LCH
- For my situation (neurodegenerative lch), which of the standard options do you recommend and why?Why: Guideline options include: MAPK-pathway inhibition (BRAF or MEK inhibitor) with neurological monitoring; early MRI detection in children with pituitary or craniofacial disease.
- Am I a candidate for Dabrafenib + trametinib, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of Dabrafenib + trametinib, Vemurafenib, LCH-III?Why: Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Why: Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Why: Supportive care improves quality of life and helps patients complete treatment.
- I read that “How long to give BRAF or MEK inhibitors and how to stop them without reactivation; combination with chemotherapy to allow cessation is being tested in the Histiocyte Society and NACHO networks”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
- I read that “Preventing and treating neurodegenerative LCH; MRI surveillance and early MAPK inhibition are the current approach”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Direct links plus the targets, companies, and technologies of this cancer's products.
technologies
6targets
1drugs
4companies
2institutions
3pathways
1terms
1trials
1bottlenecks
1Latest papers
topQuery for this cancer: (TITLE:"Langerhans cell histiocytosis" OR ABSTRACT:"Langerhans cell histiocytosis" OR TITLE:"LCH" OR ABSTRACT:"LCH" OR TITLE:"Histiocytosis X" OR ABSTRACT:"Histiocytosis X" OR TITLE:"Eosinophilic granuloma" OR ABSTRACT:"Eosinophilic granuloma" OR TITLE:"Hand-Schuller-Christian disease" OR ABSTRACT:"Hand-Schuller-Christian disease" OR TITLE:"Letterer-Siwe disease" OR ABSTRACT:"Letterer-Siwe disease") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Langerhans cell histiocytosis (LCH), not a curated reading list.
Pages like this
not linked directly; found by shared links- TrialInter-B-NHL Ritux 2010
Shares SIOP Europe – European Society for Paediatric Oncology, Children's Oncology Group (COG) and the tags nci-coverage, paediatric, haematologic.
- TrialCOG AAML0531
Shares Children's Oncology Group (COG), Acute myeloid leukaemia and the tags nci-coverage, paediatric, haematologic.
- CancerCraniopharyngioma
Shares Vemurafenib, Late effects and survivorship toxicity, Dabrafenib + trametinib, Survivorship care and late-effects surveillance and the tags nci-coverage, paediatric.
- CancerPaediatric low-grade glioma
Shares Vinblastine, Late effects and survivorship toxicity, SIOP Europe – European Society for Paediatric Oncology, Dabrafenib + trametinib and the tags nci-coverage, paediatric.
- CancerBurkitt lymphoma
Shares SIOP Europe – European Society for Paediatric Oncology, Children's Oncology Group (COG), Cytotoxic chemotherapy and the tags nci-coverage, paediatric, haematologic.
- CancerGerm cell tumours of childhood and adolescence (extracranial and CNS)
Shares Late effects and survivorship toxicity, SIOP Europe – European Society for Paediatric Oncology, Active surveillance, Survivorship care and late-effects surveillance and the tags nci-coverage, paediatric.
- CancerEpendymoma
Shares Late effects and survivorship toxicity, SIOP Europe – European Society for Paediatric Oncology, Survivorship care and late-effects surveillance, MRI and the tags nci-coverage, paediatric.
- InstitutionACCELERATE
Shares SIOP Europe – European Society for Paediatric Oncology, Rare and paediatric cancers without markets and the tags nci-coverage, paediatric.